via University of Reading
An antioxidant drug reverses atherosclerosis and could be used to prevent heart attacks and strokes due to clots, according to research funded by the British Heart Foundation (BHF) and published today in JAHA: Journal of the American Heart Association.
Atherosclerosis is the build-up of fatty deposits in the arteries. When a type of fat called LDL cholesterol becomes oxidised and builds up to form plaques in the artery walls, inflammation and damage increase which can cause the plaques to rupture and cause blood to clot.
These clots can block vital arteries that allow blood to flow to the heart, causing a heart attack, or to the brain causing a stroke.
Previously, researchers at the University of Reading discovered that LDL cholesterol can be oxidised in acidic small ‘bags’ called lysosomes in immune cells within the artery wall.
Now, Professor David Leake and his team have found that the antioxidant drug, cysteamine, has the power to switch off, and even reverse, this damaging process.
Cysteamine works by accumulating in the lysosomes and stops the oxidation of LDL cholesterol. It is already known to be safe in humans where it’s used to treat a rare lysosomal disease called cystinosis.
When the researchers looked at mice with atherosclerosis, those treated with cysteamine had a 32 to 56 per cent reduction in the size of atherosclerotic plaques depending on the part of the aorta – the largest artery in the body – that was examined.
Cysteamine decreased the amount of oxidised fat by 73 per cent and increased the stability of the atherosclerotic areas. It decreased the proportion of inflammatory white blood cells by 55 per cent and increased the area made up of smooth muscle cells by 85 per cent, ultimately reducing the chance of plaques rupturing and causing a blood clot.
Antioxidant drugs that have previously produced promising results in mice have proven disappointing in clinical trials to treat cardiovascular disease, but the researchers hope that with these promising results, cysteamine will prove a successful treatment in humans.
Professor David Leake, Professor of Biomedical Sciences at the University of Reading who led the study said:
“The potential in this drug to protect against heart attacks and strokes and ultimately save lives superseded our expectations. We hoped it would cause plaques to grow at a slower pace, but we were amazed to find it reversed the process.
“Cysteamine would offer an entirely new way of treating atherosclerosis. We now want to look at the most efficient way to give this drug to patients, and hope that it can be taken to clinical trials in the next few years.”
Professor James Leiper, Associate Medical Director at the British Heart Foundation, which funded the research said:
“Heart attacks and strokes threaten the lives of people too often. In the UK, every 5 minutes someone is admitted to hospital with a heart attack, and the same is true of stroke. “The more ways we can find to treat the root cause of cardiovascular disease, the more lives and livelihoods that can be saved.
“If this antioxidant drug can show the same promising effects in humans, then it could offer a lifeline to thousands of people in the future.”
More from: University of Reading
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- How To Fade The Dark Spots On Your Skin That Summer Left Behindon October 15, 2021 at 6:45 am
Summer is officially over, and depending on how diligent you were with sunscreen, you might have ended the season with an unwanted souvenir on your skin: dark spots. Melasma, sun spots and ...
- Cysteamine inhibits SARS-CoV-2 variants of concern in vitroon October 4, 2021 at 5:00 pm
The team – from the University of Michigan, Michigan TransTech and BIOQUAL in Rockville, Maryland – found that cysteamine hydrochloride inhibited the infectivity of multiple SARS-CoV-2 ...
- Physicist develops next-generation cancer photodrugon October 1, 2021 at 6:47 am
More information: Y. Wang et al, A new type of cuprous-cysteamine sensitizers: Synthesis, optical properties and potential applications, Materials Today Physics (2021).DOI: 10.1016/j.mtphys.2021 ...
- Copper Cysteamine Inhibits the Proliferation of Deep-Seated Tumorson September 30, 2021 at 5:01 pm
Wei Chen, professor of physics at The University of Texas at Arlington, is the senior author of two papers detailing the effects of copper cysteamine, a next-generation cancer photodrug invented in ...
- Safer treatment for deep-seated tumorson September 30, 2021 at 12:28 pm
Scientists have detailed the effects of copper cysteamine, a next-generation cancer photo-drug. Wei Chen, professor of physics at The University of Texas at Arlington, is the senior author of two ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Why Atherosclerosis first? The changing landscape of Cardiovascular Medicine and how Cardiac Computed Tomography can save liveson October 22, 2021 at 3:22 am
Computed Tomography was used for the first time on a human. Today, it is the technology that changes cardiovascular medicine.
- Invion has productive quarter following $4.5m capital raise for next-gen photodynamic therapy to treat billion-dollar diseaseson October 21, 2021 at 3:29 pm
Life sciences group Invion Group (ASX: IVX) has progressed the development of its next-generation photodynamic therapy for the treatment of various ...
- Early postmenopausal estrogen treatment reduces cardiovascular diseaseon October 19, 2021 at 3:51 am
A new study compared hormone replacement therapy (HRT) initiated close to the onset of menopause to HRT begun later. The findings were published in The New England Journal of Medicine. The authors ...
- Atherectomy Devices Market By Trends, Statistics & Regional Forecast 2021-2027on October 18, 2021 at 4:43 am
According to Global Market Insights, Inc., atherectomy devices market size is projected to surpass USD 1 billion by 2027. Significant increase in the number of hospitalizations due to rising influx of ...
- Purdue Research Foundation funds weight loss reserachon October 17, 2021 at 3:09 pm
A Purdue research study was published Aug. 8 showing that a substance previously used for Alzheimer's disease and atherosclerosis could be used for weight loss.